Snehal Patel Buys 1,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock in a transaction dated Tuesday, July 23rd. The stock was bought at an average price of $15.89 per share, with a total value of $23,835.00. Following the completion of the transaction, the chief executive officer now owns 5,527,102 shares of the company’s stock, valued at approximately $87,825,650.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Thursday, June 13th, Snehal Patel purchased 174,825 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $14.30 per share, with a total value of $2,499,997.50.

Greenwich LifeSciences Stock Up 6.9 %

Greenwich LifeSciences stock opened at $16.62 on Friday. Greenwich LifeSciences, Inc. has a 52 week low of $7.58 and a 52 week high of $21.44. The business has a 50-day simple moving average of $15.24 and a 200 day simple moving average of $13.93. The stock has a market cap of $214.07 million, a price-to-earnings ratio of -23.08 and a beta of 1.64.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its earnings results on Monday, May 20th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. On average, research analysts anticipate that Greenwich LifeSciences, Inc. will post -0.75 earnings per share for the current year.

Hedge Funds Weigh In On Greenwich LifeSciences

An institutional investor recently raised its position in Greenwich LifeSciences stock. Vanguard Group Inc. grew its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 223,102 shares of the company’s stock after purchasing an additional 1,420 shares during the period. Vanguard Group Inc. owned about 1.73% of Greenwich LifeSciences worth $4,449,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of Greenwich LifeSciences in a research report on Wednesday, May 22nd.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.